Reply: Survival benefit of transarterial chemoembolization combined with tyrosine kinase and immune checkpoint inhibitors as conversion therapy for unresectable hepatocellular carcinoma needs more details

Authors: Da-Long Yang, Yi-Fan Li, Yao-Jie Li, Guo-Gao Qiu, Zhi-Dong Liu, Yi-Ge Zhang, Huan Chen, Jian-Hong Zhong

Published: 2025-05-09

DOI: 10.1097/hep.0000000000001395

Source: Full article

No abstract found.